Company intelligence / Profile preview

Ridge Diagnostics

La Jolla, California, United Statesridgedx.com ↗

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

Ridge Diagnostics develops and markets proprietary blood-based diagnostic tests for neuropsychiatric disorders. Its lead product, the MDDScore™, provides physicians with objective biological information to aid in diagnosing and managing Major Depressive Disorder. The technology leverages a proprietary panel of serum biomarkers analyzed through its Biomarker HyperMap™ platform. Clinical data have been presented at major psychiatric congresses demonstrating utility in adolescent and young adult populations. Testing services are provided through their own CLIA-certified laboratory.

Therapeutic areas: PsychiatryNeurology
Modalities: Diagnostic test
Industry: Protein Biomarker Diagnostics

Drug pipeline

1 asset

MDDScore

Commercial

Indications: Major Depressive Disorder

Beyond the preview

Go deeper on Ridge Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ridge Diagnostics.

Explore the full profile